Page 2 - Alembic Pharma

Alembic Pharmaceuticals Q2 net profit rises 62% to Rs 2.07 billion

The revenues grew 43 per cent to Rs 11.27 billion

Alembic Pharma gets US health regulator approval for diabetes drug

The company's product is a generic version of Takeda Pharma USA's Kazano tablets, Alembic Pharmaceuticals said in a regulatory filing

Alembic Pharma shares surge 20% on USFDA nod for depression drug

The approval is for strengths of 75 mg and 100 mg

Alembic Pharmaceuticals ups its US game plan, acquires Orit

Having popular brands like Glycodin (cough syrup) in its kitty, Vadodara-headquartered Alembic had a domestic focus until a few years ago

Alembic Pharma Q2 net up 1% to Rs 121 crore

The company had posted a net profit of Rs 119.83 crore in the corresponding period of the previous fiscal

Alembic Pharma sells Baddi facility to Scott Edil for undisclosed amount

Scott Edil plans to export from the site to emerging markets; Baddi asset sold at a discounted price

Alembic Pharma opens Rs 300cr anti-cancer drug unit in Gujarat

Drug firm Alembic Pharmaceuticals Ltd (APL) today entered into oncology segment by inaugurating a Rs 300 crore anti-cancer drug facility at Halol in Gujarat. Speaking on the occasion, Chirayu Amin chairman of Alembic group of companies said the Rs 300 crore unit will manufacture 60 million tablets/capsules and approximately 20 million vials of liquid injectable and lyophilized concentrates. Gujarat Chief Minister Vijay Rupani after inaugurating plant said, "Gujarat is a leading producer with 80 per cent of pharmaceuticals products in the country and our government encourages more R&D spending for new drug discovery." The state government hopes to launch 1,000 generic medical stores in 2017 from the present 250 stores, which will help in providing cheap quality drugs to people of the state, Rupani said. He also said that Gujarat have been receiving lot of investment enquiries from global investors and we will provide conducive investment environment through new policies. With

Alembic Pharma gets USFDA nod for generic antidepressant drug

The company currently has a total of 53 ANDA approvals from the US health regulator

Alembic Pharma's partner launches drug for depressive disorder

These are therapeutically equivalent to Pristiq of Pfizer

US sales drags Alembic Pharma Q3 profit down by 67%

Domestic sales remained more or less flat during the quarter at Rs 319 cr

Alembic Pharma's Panelav unit receives Establishment Inspection Report from USFDA

Panelav makes formulations for the regulated markets and has a capacity to manufacture seven billion tablets and capsules per year

Alembic Pharma's Q1 net up by 45% at Rs 102 cr

The company's net sales rose by 25% to Rs 735 cr

Alembic Pharma says plants successfully inspected by USFDA

In April this year, the company had received four observations from the US health regulator after the inspection of Panelav facility

Alembic Pharma gets USFDA nod for seizures treatment drug

The tablets are indicated as adjunctive therapy in patients with partial onset seizures

Alembic Pharma's Panelav unit may get minor USFDA observations

The unit near Vadodara manufactures formulations and exports to the US and other regulated markets